文献速递毛发、甲与色素性疾病

deuruxolitinib治疗成人斑秃的剂量优化:2期随机试验

Dose optimization of deuruxolitinib in adults with alopecia areata: A phase 2 randomized trial.
PubMed 文献 · J Am Acad Dermatol · 2026-09-11

本2期研究(NCT03811912)将57例重度斑秃成人随机分配至deuruxolitinib 8 mg每日两次或16 mg每日一次,主要终点为第24周SALT评分相对基线变化。8 mg BID组SALT相对变化为46.4(90%CI 34.3-58.4),优于16 mg QD组的18.0(90%CI 7.6-28.4),且达到SALT≤20和≤10的患者比例更高,治疗中出现的不良事件多为轻中度。

要点

  • 8 mg BID组第24周SALT相对变化优于16 mg QD组。
  • 8 mg BID组达到SALT≤20和≤10比例更高。
  • 治疗中出现的不良事件多为轻中度。

核心结论

  • deuruxolitinib 8 mg每日两次较16 mg每日一次与头皮毛发再生改善更相关。

研究设计与样本

  • 2期随机试验(NCT03811912),57例重度斑秃成人随机分配至deuruxolitinib 8 mg BID或16 mg QD。

主要发现

  • 第24周SALT评分相对基线平均变化:8 mg BID组46.4(90%CI 34.3-58.4),16 mg QD组18.0(90%CI 7.6-28.4)。
  • 8 mg BID组达到SALT≤20和≤10的患者比例高于16 mg QD组。
  • 治疗中出现的不良事件严重程度为轻或中度。

关键数值与推荐

  • 主要终点为第24周SALT评分相对基线变化。

临床怎么用

  • 提示在重度斑秃成人中8 mg每日两次可能优于16 mg每日一次,需更大样本研究进一步验证。

局限性

  • 样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Supplementary tables: 1. BACKGROUND: The autoimmune disorder alopecia areata (AA) results in patchy or complete hair loss. OBJECTIVE: To evaluate the efficacy and safety of the Janus kinase 1/2 inhibitor deuruxolitinib dosed 8 mg twice daily (BID) or 16 mg once daily (QD) in adults with severe AA. METHODS: In this phase 2 study (NCT03811912), patients were randomized to deuruxolitinib 8 mg BID or 16 mg QD. The primary endpoint was relative change from baseline in Severity of Alopecia Tool (SALT) score at Week 24. Safety included treatment-emergent adverse events (TEAEs). RESULTS: The study included 57 patients (mean age, 40.1 years; 66.7% female). At Week 24, the mean relative change from baseline in SALT score was greater with deuruxolitinib 8 mg BID (46.4 [90% confidence interval [CI], 34.3-58.4]) vs 16 mg QD (18.0 [90% CI, 7.6-28.4]), and greater proportions of patients receiving deuruxolitinib 8 mg BID vs 16 mg QD achieved SALT score ≤20 and ≤10. TEAEs were mild or moderate in severity. LIMITATIONS: This study had a small sample size. Larger studies will further evaluate the efficacy and safety of deuruxolitinib. CONCLUSION: Deuruxolitinib 8 mg BID was associated with greater improvements in scalp hair regrowth vs deuruxolitinib 16 mg QD.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. King B, Kempers S, Mesinkovska NA, et al. Dose optimization of deuruxolitinib in adults with alopecia areata: A phase 2 randomized trial. J Am Acad Dermatol. 2026. PMID: 42727780. doi:10.1016/j.jaad.2026.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。